Biota Holdings Limited

ASX:BTA ISIN:AU000000BTA1

May 26, 2012

OVERVIEW | NEWS | MULTIMEDIA | RESEARCH

Biota Holdings Limited Company Summary

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza.

Biota research breakthroughs have included a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease, licensed to AstraZeneca and novel nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems. In addition, Biota has a key partnership with Daiichi-Sankyo for the development of second generation influenza antivirals.

Relenza(TM) is a registered trademark of the GlaxoSmithKline group of companies. *Further information available at http://www.biota.com.au

COMPANY DATA

	Headquarters	Unit 10, 585 Blackburn Road

		NOTTING HILL VIC 3168

		Australia

	Telephone	+61 3 9915 3700

	Fax	+61 3 9915 3702

	Principal Sector	Health & Pharm

	Principal Industry	Biotechnology

	Listed	1985/12/20

	Homepage	www.biota.com.au

Key Developments: Biota Holdings Limited

	iSOFT Group Limited (ASX:ISF) Appoints Dr. James Fox As Deputy Chairman MAY 31, 2010 10:52 - Article Views: 4,132 iSOFT Group Limited (ASX:ISF), Australia's largest listed health information technology company today announced the appointment of Dr. James (Jim) Fox as Deputy Chairman. This decision affirms the Board's commitment to the continual process of review and development of the Company's overall corporate governance position and the composition of the Board.

	Australian Market Report of August 13: US Economy Stabilizing AUG 13, 2009 11:15 - Article Views: 8,655 US stocks surged overnight as the Federal Reserve said the economy was leveling out, and it left interest rates unchanged at the end of its two-day policy meeting.

	iSOFT Group Limited (ASX:ISF) Appoints Dr. James Fox As Non-Executive Director JULY 8, 2009 09:57 - Article Views: 5,304 iSOFT Group Limited (ASX:ISF) Australia's largest listed health information technology company today announced the appointment of Dr. James (Jim) Fox as Non-Executive Director, as iSOFT seeks to increase the number of independent directors on its Board.

	Biota Holdings Limited (ASX:BTA) Notes Important Initiatives By GSK to Respond to the New Influenza A (H1N1) Strain MAY 4, 2009 09:25 - Article Views: 4,347 Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) notes that GlaxoSmithKline (GSK) has announced important initiatives to assist governments and health authorities around the world to respond to the emergence of the new influenza A (H1N1) strain (previously referred to as Swine Flu).

	Biota Holdings Limited (ASX:BTA) Announced Thier Relenza Royalty for March 2009 Quarter At A$32.3 Million APR 23, 2009 10:52 - Article Views: 5,174 Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that it had received notification from GlaxoSmithKline (LON:GSK) that Relenza sales were A$462 million and indicative royalties were A$32.3 million, for the three months ended 31 March 2009.

	Australian Market Report of March 30: A Slowdown after Weeks of Rallies MAR 30, 2009 13:00 - Article Views: 6,883 The Australian share closed slightly higher lifted by miners. The benchmark S&P/ASX200 index ended the day up 0.7%, or 25.7 points, at 3672.3, while the broader All Ordinaries index rose 0.8%, or 29.3 points, at 3615.6. For the week, the ASX200 added 6% and the All Ordinaries rose 6.2%.

	Biota Holdings Limited (ASX:BTA) Daiichi-Sankyo (TYO:4568) Exercise Right To Market CS-8958 In Japan MAR 30, 2009 09:41 - Article Views: 3,724 Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that Daiichi Sankyo (TYO:4568), the co-owner of the long acting neuraminidase inhibitor (LANI) CS-8958, has signed a contract to manufacture and market the product in Japan, pending the successful completion of the pivotal Phase III clinical studies and on obtaining registration approval. Biota, as one of the owners, will receive an undisclosed royalty on sales and a number of fixed sum payments on the achievement of certain sales milestones in the Japanese market.

	Biota Holdings Limited (ASX:BTA) Announces The Appointment Of Dr James Fox As Non Executive Director And Chairman MAR 2, 2009 09:58 - Article Views: 2,229 Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) announced today the appointment of Dr James Fox as a non executive Director and Chairman, effective 27 February 2008.

	Biota Holdings Limited (ASX:BTA) Interview With CEO Peter Cook FEB 18, 2009 11:58 - Article Views: 2,301 Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today reported NPAT of A$7.2 million for the first half ended December 2008, up 31 percent from the previous corresponding period. Excluding the A$20 million GlaxoSmithKline (GSK) litigation settlement, the underlying business booked a net loss of A$12.8 million for the half versus net profit of A$5.5 million previously.

	Biota Holdings Limited (ASX: BTA) Today Announces A Half Year Net Profit After Tax Of A$7.2 Million An Increase Of 31% FEB 18, 2009 09:33 - Article Views: 1,767 Biota Holdings Limited (ASX: BTA)(PINK:BTAHY) today announced a half year net profit after tax of A$7.2 million, (1H F08: A$5.5 million), a 31% improvement over first half F08. Profit before tax was A$10.1 million (1H F08: A$7.5 million) and includes A$12.7 million from the GSK litigation settlement in the period.